Yangfan Zou

Yangfan Zou

Auto-generated profile, based on publicly available information

Yangfan Zou


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 August 2026 in JMIR Preprints
Verified
Preprint
Open access
LWLei Wang
Lei Wang
YZYangfan Zou
Yangfan Zou
ZHZhaokai He
Zhaokai He
LXLiang Xia
Liang Xia
SZSongjie Zhang
Songjie Zhang
BACKGROUND Drug-related seizures require timely recognition in complex treatment settings, but spontaneous-report associations, whole-molecule features, and network-structural clues are rarely examined together. OBJECTIVE To characterize drug-related seizures by integrating pharmacovigilance, high-dimensional chemical space, machine-learning applicability, and independent network and structural analyses. METHODS We curated FAERS data from 2004Q1 through 2026Q1 and defined seizures using SEIZURE plus historical CONVULSION. After deduplication and ingredient mapping, ROR, PRR, BCPNN, and MGPS were evaluated across drug-role and indication-exclusion specifications. We analyzed ring topology, Morgan fingerprints, and USRCAT space, then audited a benchmark XGBoost model using an applicability domain and refits. Separately, 12 neuro-oncology drugs entered network analysis; FAERS-positive drugs related to at least 2 hubs underwent docking and one 100-ns molecular-dynamics trajectory per complex. RESULTS The cohort contained 167,223 unique seizure-related reports. Auditing retained 68 of 844 eligible ingredients across specifications. Morgan and USRCAT spaces showed same-label enrichment in all 8 tests (empirical P=1/10,001; all Benjamini-Hochberg significant). XGBoost held-out accuracy was 0.783 and Active recall was 0.364. Eleven of 12 primary drug structures were in-domain, although 7 had unseen Murcko scaffolds. The 486 drug-associated targets and 3951 epilepsy-associated genes shared 236 genes, yielding 15 exploratory hubs. Independently selected everolimus and vincristine were screened against human HSP90AA1 and the 5EWM cross-species interface comprising Xenopus laevis GRIN1 chain C and human GRIN2B chain D. Four trajectories showed differential behavior; vincristine-HSP90AA1 had the most consistently low RMSD profile. CONCLUSIONS Integrating reporting robustness, whole-molecule organization, model-scope auditing, and independent network-structural analysis produced a traceable strategy for prioritizing drug-context combinations and testable molecular hypotheses.